{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T09:37:05Z","timestamp":1649151425886},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00120-021-01680-9","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T16:25:43Z","timestamp":1634315143000},"page":"1391-1399","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nicht-muskelinvasives Harnblasenkarzinom (NMIBC) \u2013 Rezidivprophylaxe bei geringem und intermedi\u00e4rem Risiko"],"prefix":"10.1007","volume":"60","author":[{"given":"Georgios","family":"Gakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"issue":"4","key":"1680_CR1","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester\u00a0RJ, Rodriguez\u00a0O, Hernandez\u00a0V, Turturica\u00a0D, Bauerova\u00a0L, Bruins\u00a0HM et al (2021) European association of urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol 79(4):480\u2013488","journal-title":"Eur Urol"},{"issue":"5","key":"1680_CR2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/MOU.0b013e32833cc9f4","volume":"20","author":"G Gakis","year":"2010","unstructured":"Gakis\u00a0G, Kruck\u00a0S, Stenzl\u00a0A (2010) Can the burden of follow-up in low-grade noninvasive bladder cancer be reduced by photodynamic diagnosis, perioperative instillations, imaging, and urine markers? Curr Opin Urol 20(5):388\u2013392","journal-title":"Curr Opin Urol"},{"key":"1680_CR3","volume-title":"Krebs in Deutschland 2015\/2016","author":"Robert-Koch-Institut","year":"2016","unstructured":"Robert-Koch-Institut (2016) Krebs in Deutschland 2015\/2016"},{"issue":"3","key":"1680_CR4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester\u00a0RJ, van der Meijden\u00a0AP, Oosterlinck\u00a0W, Witjes\u00a0JA, Bouffioux\u00a0C, Denis\u00a0L et\u00a0al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a\u00a0combined analysis of 2596\u00a0patients from seven EORTC trials. Eur Urol 49(3):466\u2013465 (discussion 75\u20137)","journal-title":"Eur Urol"},{"issue":"3","key":"1680_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/BLC-160060","volume":"2","author":"G Gakis","year":"2016","unstructured":"Gakis\u00a0G, Fahmy\u00a0O (2016) Systematic review and meta-analysis on the impact of hexaminolevulinate- versus white-light guided transurethral bladder tumor resection on progression in non-muscle invasive bladder cancer. Bladder Cancer 2(3):293\u2013300","journal-title":"Bladder Cancer"},{"issue":"3","key":"1680_CR6","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.eururo.2016.03.053","volume":"70","author":"S Naito","year":"2016","unstructured":"Naito\u00a0S, Algaba\u00a0F, Babjuk\u00a0M, Bryan\u00a0RT, Sun\u00a0YH, Valiquette\u00a0L et al (2016) The clinical research office of the endourological society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1\u2011year results. Eur Urol 70(3):506\u2013515","journal-title":"Eur Urol"},{"key":"1680_CR7","unstructured":"Deutsche Krebgesellschaft (2016) S3-Leitlinie Harnblasenkarzinom (Langversion). https:\/\/www.leitlinienprogramm-onkologiede\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Blasenkarzinom\/Version_20\/LL_Harnblasenkarzinom_Langversion_20pdf. Zugegriffen: 2016"},{"issue":"4","key":"1680_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/bju.15209","volume":"127","author":"Y Kohada","year":"2021","unstructured":"Kohada\u00a0Y, Hayashi\u00a0T, Hsi\u00a0RS, Yukihiro\u00a0K, Sentani\u00a0K, Goto\u00a0K et al (2021) Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification. BJU Int 127(4):473\u2013485","journal-title":"BJU Int"},{"issue":"4","key":"1680_CR9","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","volume":"55","author":"S Gudjonsson","year":"2009","unstructured":"Gudjonsson\u00a0S, Adell\u00a0L, Merdasa\u00a0F, Olsson\u00a0R, Larsson\u00a0B, Davidsson\u00a0T et al (2009) Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a\u00a0prospective randomised multicentre study. Eur Urol 55(4):773\u2013780","journal-title":"Eur Urol"},{"issue":"3","key":"1680_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk\u00a0M, Bohle\u00a0A, Burger\u00a0M, Capoun\u00a0O, Cohen\u00a0D, Comperat\u00a0EM et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71(3):447\u2013461","journal-title":"Eur Urol"},{"issue":"4","key":"1680_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00345-011-0691-2","volume":"29","author":"C De Nunzio","year":"2011","unstructured":"De Nunzio\u00a0C, Carbone\u00a0A, Albisinni\u00a0S, Alpi\u00a0G, Cantiani\u00a0A, Liberti\u00a0M et al (2011) Long-term experience with early single mitomycin C instillations in patients with low-risk non-muscle-invasive bladder cancer: prospective, single-centre randomised trial. World J Urol 29(4):517\u2013521","journal-title":"World J Urol"},{"key":"1680_CR12","first-page":"1","volume":"7","author":"H Ersoy","year":"2013","unstructured":"Ersoy\u00a0H, Yaytokgil\u00a0M, Karakoyunlu\u00a0AN, Topaloglu\u00a0H, Sagnak\u00a0L, Ozok\u00a0HU (2013) Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a\u00a0preliminary study. Drug Des Devel Ther 7:1\u20136","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"1680_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00345-018-2196-8","volume":"36","author":"R Tanimoto","year":"2018","unstructured":"Tanimoto\u00a0R, Saika\u00a0T, Ebara\u00a0S, Kobayashi\u00a0Y, Nasu\u00a0R, Yamada\u00a0D et al (2018) Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation. World J Urol 36(6):889\u2013895","journal-title":"World J Urol"},{"issue":"3","key":"1680_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.eururo.2009.06.010","volume":"56","author":"A Bohle","year":"2009","unstructured":"Bohle\u00a0A, Leyh\u00a0H, Frei\u00a0C, Kuhn\u00a0M, Tschada\u00a0R, Pottek\u00a0T et al (2009) Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a\u00a0randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol 56(3):495\u2013503","journal-title":"Eur Urol"},{"issue":"2","key":"1680_CR15","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/bju.13599","volume":"119","author":"T Onishi","year":"2017","unstructured":"Onishi\u00a0T, Sugino\u00a0Y, Shibahara\u00a0T, Masui\u00a0S, Yabana\u00a0T, Sasaki\u00a0T (2017) Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle-invasive bladder cancer. BJU Int 119(2):276\u2013282","journal-title":"BJU Int"},{"issue":"2","key":"1680_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4103\/iju.IJU_371_16","volume":"33","author":"P Bijalwan","year":"2017","unstructured":"Bijalwan\u00a0P, Pooleri\u00a0GK, Thomas\u00a0A (2017) Comparison of sterile water irrigation versus intravesical mitomycin C in preventing recurrence of nonmuscle invasive bladder cancer after transurethral resection. Indian J Urol 33(2):144\u2013148","journal-title":"Indian J Urol"},{"issue":"2","key":"1680_CR17","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.eururo.2017.06.038","volume":"73","author":"J Bosschieter","year":"2018","unstructured":"Bosschieter\u00a0J, Nieuwenhuijzen\u00a0JA, van Ginkel\u00a0T, Vis\u00a0AN, Witte\u00a0B, Newling\u00a0D et al (2018) Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243\u00a0patients. Eur Urol 73(2):226\u2013232","journal-title":"Eur Urol"},{"issue":"2","key":"1680_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstrom","year":"2009","unstructured":"Malmstrom\u00a0PU, Sylvester\u00a0RJ, Crawford\u00a0DE, Friedrich\u00a0M, Krege\u00a0S, Rintala\u00a0E et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 56(2):247\u2013256","journal-title":"Eur Urol"},{"key":"1680_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/bju.15571","author":"Y Miyata","year":"2021","unstructured":"Miyata\u00a0Y, Tsurusaki\u00a0T, Hayashida\u00a0Y, Imasato\u00a0Y, Takehara\u00a0K, Aoki\u00a0D et al (2021) Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non-muscle-invasive bladder cancer: a randomised clinical trial. BJU Int. https:\/\/doi.org\/10.1111\/bju.15571","journal-title":"BJU Int"},{"issue":"3","key":"1680_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3109\/02656736.2014.900194","volume":"30","author":"A Sousa","year":"2014","unstructured":"Sousa\u00a0A, Inman\u00a0BA, Pineiro\u00a0I, Monserrat\u00a0V, Perez\u00a0A, Aparici\u00a0V et al (2014) A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer. Int J Hyperthermia 30(3):166\u2013170","journal-title":"Int J Hyperthermia"},{"issue":"1","key":"1680_CR21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/2090598X.2021.1874627","volume":"19","author":"F Chiancone","year":"2021","unstructured":"Chiancone\u00a0F, Fabiano\u00a0M, Carrino\u00a0M, Fedelini\u00a0M, Meccariello\u00a0C, Fedelini\u00a0P (2021) Impact of systemic inflammatory markers on the response to hyperthermic intraVEsical chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette-Guerin failure. Arab J Urol 19(1):86\u201391","journal-title":"Arab J Urol"},{"issue":"6","key":"1680_CR22","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/bju.15038","volume":"125","author":"AH Mostafid","year":"2020","unstructured":"Mostafid\u00a0AH, Porta\u00a0N, Cresswell\u00a0J, Griffiths\u00a0TRL, Kelly\u00a0JD, Penegar\u00a0SR et al (2020) CALIBER: a\u00a0phase II randomized feasibility trial of chemoablation with mitomycin\u2011C vs surgical management in low-risk non-muscle-invasive bladder cancer. BJU Int 125(6):817\u2013826","journal-title":"BJU Int"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01680-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-021-01680-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-021-01680-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T11:38:10Z","timestamp":1636025890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-021-01680-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1007\/s00120-021-01680-9","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"assertion":[{"value":"16 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Gakis gibt an (vergangene drei Jahre): T\u00e4tigkeiten im Advisory Board (MSD, Merck, Leo Pharma, Bayer, Astellas, Roche, BMS) und Honorart\u00e4tigkeiten\/Vortr\u00e4ge (medac, Ipsen Pharma, Erbe Elektromedizin, Roche, MSD).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}